Blueprint is an early-state biotech firm that is developing anti-cancer treatments. Its shares are up approximately 60 percent in the past year.
On why the company's shares rallied: "I think it's a reflection of a couple of factors. First off, late in the year we shared data at medical conferences for three different diseases that showed early activity in areas where there is a clear medical need. Secondly, we filed an application with the FDA that's now been accepted," he said. "We signed a collaboration with Roche out of Switzerland."
Albers also commented on what differentiates the company, the criteria for partnerships and the upcoming catalysts for the shares.
To watch the interview in its entirety, you must be a CNBC PRO subscriber.